Compare Flux Power Holdings Inc (FLUX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flux Power Holdings Inc vs Merck & Co., Inc. — how do they compare? Flux Power Holdings Inc trades at $0.68 (market cap $15.37M), while Merck & Co., Inc. trades at $123.63 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 19862.7× Flux Power Holdings Inc's market cap, and Merck & Co., Inc. pays a 2.75% dividend while Flux Power Holdings Inc pays none. Which is the better fit depends on your goals.
| FLUX | MRK | |
|---|---|---|
Market Cap | $15.37M | $305.29B |
Sector | Utilities | Health |
52-Week High | $6.66 | $129.52 |
52-Week Low | $0.71 | $77.60 |
Enterprise Value | $21.53M | $348.71B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.689, down 3.85% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $6.67 million in 2025 and a negative net income margin of -12.48% in 2026, though revenue remains substantial. Recent news highlights product innovation with the launch of SkyEMS 3.0 and new executive appointments aimed at growth. Analyst consensus is unanimously bullish with 6 buy ratings.
The outlook is mixed: strong analyst support and strategic developments offer upside potential, but persistent losses and bearish technicals pose significant risks. Investors must weigh growth initiatives against profitability challenges and market volatility.
MRK's stock trades at $128.08, up 6.02% over the past day, reflecting strong momentum. The technical outlook is bullish based on moving averages, with key support at $121 and resistance at $126. Fundamentally, the company reported $65.01B in 2025 revenue with a net income margin of 13.59%, and recent earnings beats in Q3 2025 and Q4 2025 highlight operational strength. The pending acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, signaling strategic growth initiatives.
The investment outlook for MRK is positive, supported by analyst consensus with a $137.30 price target and 67.57% buy ratings. Key opportunities include robust profitability and pipeline expansion via M&A, while risks involve rising debt levels and competitive pressures in the pharmaceutical sector. Earnings growth and successful integration of acquisitions are critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
